CytoMed Therapeutics Limited (GDTC)

NASDAQ: GDTC · IEX Real-Time Price · USD
2.105
+0.035 (1.69%)
At close: Apr 11, 2024, 4:00 PM
2.000
-0.105 (-4.99%)
Pre-market: Apr 15, 2024, 4:35 AM EDT
1.69%
Market Cap 24.21M
Revenue (ttm) n/a
Net Income (ttm) -3.16M
Shares Out 11.53M
EPS (ttm) -0.36
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 866
Open 2.100
Previous Close 2.070
Day's Range 2.100 - 2.129
52-Week Range 1.920 - 9.250
Beta n/a
Analysts Buy
Price Target 5.00 (+137.53%)
Earnings Date n/a

About GDTC

CytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers in Malaysia and Singapore. Its lead product candidate is CTM-N2D, which is in Phase I clinical trials comprising expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor to improve anti-cancer cytotoxicity. The company is also developing iPSC-gdNKT, which utilizes iPSC as a starting material to generate gdNKT, a synthetic hybrid of a... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Apr 14, 2023
Employees 27
Stock Exchange NASDAQ
Ticker Symbol GDTC
Full Company Profile

Financial Performance

Financial numbers in SGD Financial Statements

Analyst Forecast

According to one analyst, the rating for GDTC stock is "Buy" and the 12-month stock price forecast is $5.0.

Price Target
$5.0
(137.53% upside)
Analyst Consensus: Buy
Stock Forecasts

News

CytoMed Diversifies into Regenerative Medicine after Research Collaboration with Singapore's Sengkang General Hospital to Test Injectable Umbilical Cord-Derived Mesenchymal Stem Cells for Cartilage Regeneration

SINGAPORE / ACCESSWIRE / March 20, 2024 / CytoMed Therapeutics Limited (NASDAQ:GDTC) ("CytoMed" or "the Company"), a Singapore biopharmaceutical company that focuses on utilizing its licensed propriet...

25 days ago - Accesswire

CytoMed Therapeutics to Launch Complimentary Cell Banking for Qualified Shareholders for Future Precision Therapies

SINGAPORE, March 18, 2024 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or “Company”), a Singapore-based biopharmaceutical company focused on harnessing its proprietary te...

27 days ago - GlobeNewsWire

CytoMed Therapeutics Limited Announces Research Collaboration with Singapore Sengkang General Hospital to Advance Injectable Umbilical Cord-Derived Mesenchymal Stem Cells for Cartilage Diseases and Repair

SINGAPORE, March 04, 2024 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or “Company”), a Singapore-based biopharmaceutical company focused on harnessing its proprietary te...

5 weeks ago - GlobeNewsWire

Malaysian Patent Granted for CytoMed Therapeutics' Licensed Allogeneic CAR-Gamma Delta T Cell Technology

The Company now has exclusive rights to a Malaysia, US and China patent The Company now has exclusive rights to a Malaysia, US and China patent

2 months ago - GlobeNewsWire

CytoMed Therapeutics Signs HOA and MOU to Advance Research on Allogeneic Gamma Delta T Cell Technology

SINGAPORE , Dec. 5, 2023 /PRNewswire/ -- CytoMed Therapeutics Limited (NASDAQ: GDTC) ("CytoMed" or "Company"), a Singapore-based biopharmaceutical company focused on harnessing its proprietary technol...

4 months ago - PRNewsWire

CytoMed Therapeutics Reports First Half 2023 Financial Report and Provides Corporate Update

Conference call webcast is scheduled for November 22 at 9 a.m. ET. SINGAPORE , Nov. 17, 2023 /PRNewswire/ -- CytoMed Therapeutics Limited (NASDAQ: GDTC) ("CytoMed" or "Company"), a Singapore-based bio...

5 months ago - PRNewsWire

CytoMed Therapeutics to Present at The Benchmark Company's Upcoming Discovery One-on-One Investor Conference

SINGAPORE , Nov. 14, 2023 /PRNewswire/ -- CytoMed Therapeutics Limited (NASDAQ: GDTC) ("CytoMed" or "Company"), a Singapore-based biopharmaceutical company focused on harnessing its proprietary techno...

5 months ago - PRNewsWire

CytoMed Therapeutics Adds to its Intellectual Portfolio After Securing Chinese Patent for its Licensed iPSC-Based Technology

SINGAPORE / ACCESSWIRE / October 24, 2023 / CytoMed Therapeutics Limited (NASDAQ:GDTC) ("CytoMed" or "the Company"), a Singapore biopharmaceutical company focused on utilizing its licensed proprietary...

6 months ago - Accesswire

Chinese Patent Granted for CytoMed Therapeutics' Licensed iPSC-Based Technology

SINGAPORE , Sept. 25, 2023 /PRNewswire/ -- CytoMed Therapeutics Limited (NASDAQ: GDTC) ("CytoMed" or "Company"), a Singapore-based biopharmaceutical company focused on harnessing its proprietary techn...

7 months ago - PRNewsWire

CytoMed Expands Research Collaboration into China After Entering Into MOU

SINGAPORE / ACCESSWIRE / August 29, 2023 / CytoMed Therapeutics Limited (NASDAQ:GDTC) ("CytoMed" or "the Company"), a Singapore biopharmaceutical company focused on utilizing its licensed proprietary ...

8 months ago - Accesswire

CytoMed Therapeutics Limited to Present at the August 24th Virtual Investor Summit

Singapore, Singapore--(Newsfile Corp. - August 17, 2023) - CytoMed Therapeutics Limited (NASDAQ: GDTC) ("CytoMed" or "Company") announced today it will be presenting at the August 24th, 2023 virtual I...

8 months ago - Newsfile Corp

CytoMed Therapeutics Announces China Research Collaboration to Enhance its Allogeneic CAR γD T In Vivo Persistency

The MOU signed by CytoMed and Hangzhou CNK Therapeutics Co., Ltd is the first of several collaborative efforts in North Asia.   SINGAPORE , Aug. 15, 2023 /PRNewswire/ -- CytoMed Therapeutics Limited (...

8 months ago - PRNewsWire

Chinese Patent Granted for A*STAR Spinoff, CytoMed Therapeutics' Licensed Allogeneic CAR-Gamma Delta T Cell Technology

The Company now has exclusive rights to a US and Chinese patent. SINGAPORE , Aug. 1, 2023 /PRNewswire/ -- CytoMed Therapeutics Limited (NASDAQ: GDTC) ("CytoMed" or "Company"), a Singapore-based biopha...

9 months ago - PRNewsWire

CytoMed Therapeutics Announces U.S. Patent Granted For its Licensed, Novel CAR-Gamma Delta T Cell Technology

SINGAPORE / ACCESSWIRE / July 27, 2023 / CytoMed Therapeutics Limited (NASDAQ:GDTC) ("CytoMed" or "the Company"), a Singapore biopharmaceutical company focused on utilizing its licensed proprietary te...

9 months ago - Accesswire

A*STAR Spinoff CytoMed Therapeutics Announce a Patent for its Licensed CAR-Gamma Delta T Cell Technology Has Been Granted in the US

SINGAPORE , July 6, 2023 /PRNewswire/ -- CytoMed Therapeutics Limited (NASDAQ: GDTC) ("CytoMed" or "Company"), a Singapore-based biopharmaceutical company focused on harnessing its proprietary technol...

10 months ago - PRNewsWire

CytoMed Therapeutics to Ring Nasdaq Closing Bell

SINGAPORE , May 11, 2023 /PRNewswire/ -- CytoMed Therapeutics Limited ("CytoMed" or the "Company") (Nasdaq: GDTC), a biopharmaceutical company focused on harnessing its licensed proprietary technologi...

1 year ago - PRNewsWire

CytoMed Therapeutics Limited Announces Collaboration with MD Anderson Cancer Center to Advance Allogeneic Off-the-Shelf Gamma Delta T Cells in Oncology

SINGAPORE , May 9, 2023 /PRNewswire/ -- CytoMed Therapeutics Limited (Nasdaq: GDTC) ("CytoMed" or the "Company"), a biopharmaceutical company focused on harnessing its licensed proprietary technologie...

1 year ago - PRNewsWire

CytoMed Therapeutics Limited Announces Pricing of Initial Public Offering

SINGAPORE, April 13, 2023 /PRNewswire/ -- CytoMed Therapeutics Limited ("CytoMed" or the "Company"), a pre-clinical biopharmaceutical company focused on harnessing its licensed proprietary technologie...

1 year ago - PRNewsWire